Skip to content

Solid Biosciences Inc. SLDB Change in Other Assets

Change in Other Assets at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$14.55M-3.5%
Insmed logo
InsmedINSM
$2.36M+123%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$28K
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$794K-24.5%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
-$3.05M-306%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$247K-61.0%

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$872.26M+135%
Enterprise value$595.83M+223%
P/S107.8×-9.9×

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solid Biosciences Inc.'s change in other assets?
Solid Biosciences Inc. (SLDB) reported change in other assets of -$954K in Q1 2026.
How has Solid Biosciences Inc.'s change in other assets changed year-over-year?
Solid Biosciences Inc.'s change in other assets increased by 52.8% year-over-year, from -$2.02M to -$954K.
What does change in other assets mean?
Change in miscellaneous assets affecting operating cash flow.